Clinical Development Program Appropriate for Rolling BLA Submission Expected by the End of 2025CANTON, Mass., Dec. 15, 2025 (GLOBE NEWSWIRE) -- ...

The majority of knees without radiographic osteoarthritis experience an increase in structural damage over time, with the most frequent changes being observed in the patellofemoral joint.

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

Topline phase 3 results show retatrutide led to meaningful weight reduction and pain relief in adults with overweight or obesity and knee OA.

Eli Lilly drug candidate retatrutide achieved up to 28.7% weight loss and reduced knee osteoarthritis pain in a phase 3 trial of 445 adults.

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

A novel triple receptor agonist conferred weight loss of up to 28.7% at 68 weeks and reductions in pain for adults with ...

Professional organizations such as the American College of Rheumatology and the American Academy of Orthopaedic Surgeons strongly recommend exercise and other conservative modalities of care prior to ...

Lilly reports Phase 3 data showing retatrutide delivered substantial weight loss, reduced knee pain, and improved ...

Eli Lilly's "triple g" drug helped patients lose about 28.7% of their body weight while also reducing pain associated with knee osteoarthritis in a Phase 3 trial. One of Eli Lilly's most promising new ...

Toomey, an associate professor at the School of Allied Health at the University of Limerick in Ireland, told Fit&Well: ...

Knee braces and water-based exercise appear to be two of the most effective ways to ease the pain and stiffness caused by knee osteoarthritis. That is according to a review of 12 non-drug therapies, ...